110 related articles for article (PubMed ID: 12084457)
21. Differential DNA recognition by the enantiomers of 1-Rh(MGP)2 phi: a combination of shape selection and direct readout.
Franklin SJ; Barton JK
Biochemistry; 1998 Nov; 37(46):16093-105. PubMed ID: 9819202
[TBL] [Abstract][Full Text] [Related]
22. Discovery of indeno[1, 2 - c] quinoline derivatives as dual topoisomerases I/II inhibitors: part 3.
Tseng CH; Tzeng CC; Yang CL; Lu PJ; Liu YP; Chen HL; Chen CY; Yang CN; Chen YL
Mol Divers; 2013 Nov; 17(4):781-799. PubMed ID: 24022468
[TBL] [Abstract][Full Text] [Related]
23. 1H- and 31P-NMR studies of ditercalinium binding to a d(GCGC)2 and d(CCTATAGG)2 minihelices: a sequence specificity study.
Delepierre M; Milhe C; Namane A; Dinh TH; Roques BP
Biopolymers; 1991 Feb; 31(3):331-53. PubMed ID: 1868161
[TBL] [Abstract][Full Text] [Related]
24. DNA topoisomerase II poison TAS-103 transactivates GC-box-dependent transcription via acetylation of Sp1.
Torigoe T; Izumi H; Wakasugi T; Niina I; Igarashi T; Yoshida T; Shibuya I; Chijiiwa K; Matsuo K; Itoh H; Kohno K
J Biol Chem; 2005 Jan; 280(2):1179-85. PubMed ID: 15533934
[TBL] [Abstract][Full Text] [Related]
25. Ethidium bromide-(dC-dG-dC-dG)2 complex in solution: intercalation and sequence specificity of drug binding at the tetranucleotide duplex level.
Patel DJ; Canuel LL
Proc Natl Acad Sci U S A; 1976 Oct; 73(10):3343-7. PubMed ID: 1068447
[TBL] [Abstract][Full Text] [Related]
26. A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor.
Morrell A; Antony S; Kohlhagen G; Pommier Y; Cushman M
J Med Chem; 2006 Dec; 49(26):7740-53. PubMed ID: 17181156
[TBL] [Abstract][Full Text] [Related]
27. Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer.
Ewesuedo RB; Iyer L; Das S; Koenig A; Mani S; Vogelzang NJ; Schilsky RL; Brenckman W; Ratain MJ
J Clin Oncol; 2001 Apr; 19(7):2084-90. PubMed ID: 11283142
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives. Part 2.
Tseng CH; Tzeng CC; Yang CL; Lu PJ; Chen HL; Li HY; Chuang YC; Yang CN; Chen YL
J Med Chem; 2010 Aug; 53(16):6164-79. PubMed ID: 20662543
[TBL] [Abstract][Full Text] [Related]
29. Two-dimensional 1H and 31P NMR spectra of a decamer oligodeoxyribonucleotide duplex and a quinoxaline ((MeCys3, MeCys7)(TANDEM) drug duplex complex.
Powers R; Olsen RK; Gorenstein DG
J Biomol Struct Dyn; 1989 Dec; 7(3):515-56. PubMed ID: 2627298
[TBL] [Abstract][Full Text] [Related]
30. The interaction of ellipticine derivatives with nucleic acids studied by optical and 1H-nmr spectroscopy: effect of size of the heterocyclic ring system.
Behravan G; Leijon M; Sehlstedt U; Nordén B; Vallberg H; Bergman J; Gräslund A
Biopolymers; 1994 May; 34(5):599-609. PubMed ID: 8003620
[TBL] [Abstract][Full Text] [Related]
31. Flavopiridol binds to duplex DNA.
Bible KC; Bible RH; Kottke TJ; Svingen PA; Xu K; Pang YP; Hajdu E; Kaufmann SH
Cancer Res; 2000 May; 60(9):2419-28. PubMed ID: 10811119
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic efficacy of a new topoisomerase I and II inhibitor TAS-103, against both P-glycoprotein-expressing and -nonexpressing drug-resistant human small-cell lung cancer.
Parajuli P; Yano S; Nishioka Y; Nokihara H; Hanibuchi M; Nishimura N; Utsugi T; Sone S
Oncol Res; 1999; 11(5):219-24. PubMed ID: 10608616
[TBL] [Abstract][Full Text] [Related]
33. DNA sequence selectivity of topoisomerases and topoisomerase poisons.
Capranico G; Binaschi M
Biochim Biophys Acta; 1998 Oct; 1400(1-3):185-94. PubMed ID: 9748568
[TBL] [Abstract][Full Text] [Related]
34. Structure of gene 5 protein-oligodeoxynucleotide complexes as determined by 1H, 19F, and 31P nuclear magnetic resonance.
Coleman JE; Anderson RA; Ratcliffe RG; Armitage IM
Biochemistry; 1976 Dec; 15(25):5419-30. PubMed ID: 999816
[TBL] [Abstract][Full Text] [Related]
35. 1H NMR studies of the bis-intercalation of a homodimeric oxazole yellow dye in DNA oligonucleotides.
Johansen F; Jacobsen JP
J Biomol Struct Dyn; 1998 Oct; 16(2):205-22. PubMed ID: 9833661
[TBL] [Abstract][Full Text] [Related]
36. The binding of manganese(II) and zinc(II) to the synthetic oligonucleotide d(C-G-C-G-A-A-T-T-C-G-C-G)2. A 1H NMR study.
Frøystein NA; Sletten E
Acta Chem Scand (Cph); 1991 Mar; 45(3):219-25. PubMed ID: 2039665
[TBL] [Abstract][Full Text] [Related]
37. An NMR investigation of the binding of the anticancer drug actinomycin D to oligodeoxyribonucleotides with isolated 5'd(GC)3' binding sites.
Jones RL; Scott EV; Zon G; Marzilli LG; Wilson WD
Biochemistry; 1988 Aug; 27(16):6021-6. PubMed ID: 3191105
[TBL] [Abstract][Full Text] [Related]
38. Dual topoisomerase I/II inhibitors in cancer therapy.
Denny WA; Baguley BC
Curr Top Med Chem; 2003; 3(3):339-53. PubMed ID: 12570767
[TBL] [Abstract][Full Text] [Related]
39. Exploring the DNA binding/cleavage, cellular accumulation and topoisomerase inhibition of 2-hydroxy-3-(aminomethyl)-1,4-naphthoquinone Mannich bases and their platinum(II) complexes.
Neves AP; Pereira MX; Peterson EJ; Kipping R; Vargas MD; Silva FP; Carneiro JW; Farrell NP
J Inorg Biochem; 2013 Feb; 119():54-64. PubMed ID: 23186648
[TBL] [Abstract][Full Text] [Related]
40. Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor.
Park S; Thapa Magar TB; Kadayat TM; Lee HJ; Bist G; Shrestha A; Lee ES; Kwon Y
Eur J Med Chem; 2017 Feb; 127():318-333. PubMed ID: 28068603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
